Compare VRME & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRME | TOVX |
|---|---|---|
| Founded | 1999 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2M | 10.1M |
| IPO Year | 2013 | 2012 |
| Metric | VRME | TOVX |
|---|---|---|
| Price | $0.72 | $0.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $1.50 | $1.00 |
| AVG Volume (30 Days) | 40.2K | ★ 456.9K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 89.07 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $16,398,000.00 | N/A |
| Revenue This Year | $36.85 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.59 | $0.16 |
| 52 Week High | $1.51 | $0.86 |
| Indicator | VRME | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 58.20 | 54.29 |
| Support Level | $0.66 | $0.22 |
| Resistance Level | $0.74 | $0.26 |
| Average True Range (ATR) | 0.04 | 0.01 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 83.47 | 54.52 |
VerifyMe Inc is a logistics company that specializes in time and temperature-sensitive products, as well as providing brand protection and enhancement solutions. The company operates through two reportable business segments: Precision Logistics offers a value-added service provider for time and temperature-sensitive parcel management. Using a proprietary IT platform, it provides real-time information and analysis to mitigate supply chain flow interruption, delivering last-mile resolution for key markets, including the perishable healthcare and food industries; and the Authentication segment specializes in anti-counterfeit and brand protection. The Precision Logistics segment derives the majority of the revenue.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.